Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
MMV371
AOB18144
CAS: 1080645-02-8
Chemical Name: mCBE161; 3-((1r,4r)-4-(4-Chlorophenyl)cyclohexyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate
2500 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $73.95 | Total: $369.75 |
| 1 | 10 | $62.64 | Total: $626.40 |
| 1 | 25 | $53.07 | Total: $1,326.75 |
| 1 | 50 | $45.24 | Total: $2,262.00 |
| 1 | 100 | $39.15 | Total: $3,915.00 |
Overview
MMV371 is a long-acting injectable (LAI) antimalarial drug developed by Medicines for Malaria Venture (MMV). It is designed to provide extended protection against malaria with a single intramuscular dose.
Mechanism of Action
MMV371 is a prodrug of atovaquone, a well-established antimalarial agent. By attaching an ester-linked acetyl group to atovaquone, MMV371 is designed to remain inactive until it is metabolized in the body. This modification allows for prolonged circulation and extended pharmacological activity. In preclinical studies, a single intramuscular injection of MMV371 maintained atovaquone levels above the minimum effective concentration for up to 69 days, compared to 21 days with atovaquone alone. Scripps Research
Target Parasites
MMV371 targets the mitochondrial cytochrome bc1 complex, inhibiting the electron transport chain in the malaria parasite. This action disrupts energy production, leading to parasite death. It is effective against both Plasmodium falciparum and Plasmodium vivax, the two most prevalent malaria parasites. mmv.org
Clinical Development
A Phase 1 clinical trial for MMV371 commenced in 2024 in Nottingham, UK. The trial aims to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers. Pending successful outcomes, clinical trials in malaria-endemic regions are anticipated to begin in 2026. Scripps Research
Potential Benefits
Extended Protection: A single dose could offer up to three months of protection against malaria.
Simplified Dosing: Reduces the need for daily medication, improving patient compliance.
Asymptomatic Infection Clearance: Potential to clear asymptomatic malaria infections, reducing transmission.
Affordability: Designed to be cost-effective, making it accessible in resource-limited settings. Quotient Sciences
Chemical Properties
| Molecular Formula | C24H21ClO4 |
| Molecular Weight | 408.88 |
| CAS Numbers | 1080645-02-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | 3-((1r,4r)-4-(4-Chlorophenyl)cyclohexyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Synonyms
MMV 371; MMV-371; mCBE161
References
1) Myriam El Gaaloul et. al.; Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile, Malaria Journal volume 23, Article number: 315 (2024)